Anima vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 39)
Anima logo

Anima

EmergingHealthcare

General

AI care enablement platform resolving 85% of patient inquiries within one day; $12M Series A from Molten Ventures helping clinics manage NHS and value-based care patient caseloads.

AI VisibilityBeta
Overall Score
D39
Category Rank
#440 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
43
Perplexity
45
Gemini
44

About

Anima is a care enablement platform that uses AI to help clinical teams manage patient caseloads more efficiently — enabling practices, clinics, and healthcare systems to handle more patient inquiries with the same clinical staff by triaging, routing, and pre-processing patient messages, symptoms, and administrative requests before they reach clinicians. Founded as a Y Combinator W21 graduate, Anima raised $14.5 million total including a $12 million Series A in early 2024 led by Molten Ventures with Hummingbird, achieving a benchmark of resolving 85% of patient inquiries within one day.\n\nAnima's platform integrates with existing EHR systems and clinical workflows — when patients submit messages or requests, Anima's AI layer categorizes the urgency, extracts relevant clinical context from the patient record, and routes to the appropriate care team member with pre-populated response templates and suggested actions. Administrative inquiries (prescription refills, appointment requests, test result questions) are handled with AI-assisted responses that clinicians can review and approve rapidly rather than composing from scratch. This reduces the cognitive load of clinical inbox management that contributes to physician burnout.\n\nIn 2025, Anima competes in the clinical workflow automation and care management platform market with Klara (patient communication), Luma Health (care orchestration), Healthie, and AI-powered EHR tools from Epic and athenahealth for clinical team productivity and patient communication. The UK National Health Service (NHS) has been a key market for Anima, given the NHS's acute GP workload crisis and the need for digital tools that help manage the high volume of patient contacts with limited clinical capacity. The 2025 strategy focuses on expanding within NHS primary care networks, growing in US value-based care organizations where managing population health efficiently is financially incentivized, and deepening AI capabilities for clinical decision support.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

39
Overall Score
88
#440
Category Rank
#3
73
AI Consensus
78
stable
Trend
stable
43
ChatGPT
83
45
Perplexity
87
44
Gemini
85
34
Claude
90
41
Grok
92

Key Details

Category
General
AI Drug Discovery
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.